<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396707</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-1101</org_study_id>
    <nct_id>NCT01396707</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)</brief_title>
  <acronym>Her+XELOX</acronym>
  <official_title>A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicentre, prospective phase II trial designed to evaluate the
      efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as
      first-line therapy in patients with recurrent and/or metastatic HER2 positive adenocarcinoma
      of the stomach or gastro-oesophageal junction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be administered 6 cycles of combination chemotherapy, unless withdrawn earlier
      due to unacceptable toxicity, disease progression, or consent withdrawal. Patients will
      continue to be treated with trastuzumab alone until disease progression, unacceptable
      toxicity or consent withdrawal after finishing a maximum 6 cycles of combination
      chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the overall response rate for patients treated with trastuzumab combinated with capecitabine plus oxaliplatin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Metastatic or Recurrent Gastric Adenocarcinoma</condition>
  <condition>Her-2 Positive Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Herceptin+XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin+XELOX</intervention_name>
    <description>Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression
Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks
Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)
Oxaliplatin 130 mg/m2 i.v. on day 1</description>
    <arm_group_label>Herceptin+XELOX</arm_group_label>
    <other_name>Trastuzumab</other_name>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction
             with inoperable locally advanced or recurrent and/or metastatic disease, not amenable
             to curative therapy.

          2. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
             (RECIST), assessed using imaging techniques (CT or MRI).

          3. HER2 positive tumour (primary tumour or metastasis) defined as either IHC2+ and FISH+
             or IHC3+ according to the gastric cancer scoring system for HER2

          4. ECOG Performance status 0, 1 or 2

          5. Life expectancy of at least 3 months.

          6. Male or female. Age over 20 year.

          7. Signed informed consent.

        Exclusion Criteria:

          1. Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant
             therapy is allowed if at least 6 months has elapsed between completion of
             adjuvant/neoadjuvant therapy and enrolment into the study; adjuvant/neoadjuvant
             therapy with platinum is not allowed).

          2. Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not
             those with a jejunostomy tube).

          3. Patients with active (significant or uncontrolled) gastrointestinal bleeding.

          4. Residual relevant toxicity resulting from previous therapy (with the exception of
             alopecia), e.g. neurological toxicity over grade 2 NCI-CTCAE.

          5. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
             or basal cell carcinoma.

          6. Neutrophil count &lt; 1.5 × 109/L, or platelet count &lt; 100 × 109/L.

          7. Serum bilirubin &gt; 1.5 × upper limit of normal (ULN); or, AST or ALT &gt; 2.5 × ULN (or &gt;
             5 × ULN in patients with liver metastases); or, alkaline phosphatase &gt; 2.5 × ULN (or &gt;
             5 × ULN in patients with liver metastases, or &gt; 10 × ULN in patients with bone but no
             liver metastases); or, albumin &lt; 25 g/L.

          8. Creatinine clearance &lt; 60 mL/min. Other Study Drug-Related Exclusion Criteria

          9. History of documented congestive heart failure; angina pectoris requiring medication;
             evidence of transmural myocardial infarction on ECG; poorly controlled hypertension
             (systolic BP &gt; 180 mmHg or diastolic BP &gt; 100 mmHg); clinically significant valvular
             heart disease; or high risk uncontrollable arrhythmias.

         10. Baseline LVEF &lt; 50% (measured by echocardiography or MUGA).

         11. Patients with dyspnea at rest due to complications of advanced malignancy or other
             disease, or who require supportive oxygen therapy.

         12. Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and
             short courses of oral steroids for anti-emesis or as an appetite stimulant are
             allowed).

         13. Clinically significant hearing abnormality.

         14. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

         15. History or clinical evidence of brain metastases.

         16. Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly
             controlled diabetes.

         17. Positive serum pregnancy test in women of childbearing potential.

         18. Subjects with reproductive potential not willing to use an effective method of
             contraception.

         19. Received any investigational drug treatment within 4 weeks of start of study
             treatment.

         20. Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if
             palliative radiotherapy given to bone metastatic site peripherally and patient
             recovered from any acute toxicity).

         21. Major surgery within 4 weeks of start of study treatment, without complete recovery.

         22. History of HIV infection, Patients with known active infection with HBV, or HCV.

         23. Known hypersensitivity to any of the study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1.</citation>
    <PMID>10200776</PMID>
  </reference>
  <reference>
    <citation>Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1;72(1):37-41.</citation>
    <PMID>8508427</PMID>
  </reference>
  <reference>
    <citation>Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163-8.</citation>
    <PMID>9093725</PMID>
  </reference>
  <reference>
    <citation>Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91.</citation>
    <PMID>7533517</PMID>
  </reference>
  <reference>
    <citation>Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813-8.</citation>
    <PMID>8508349</PMID>
  </reference>
  <reference>
    <citation>Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9.</citation>
    <PMID>12506170</PMID>
  </reference>
  <reference>
    <citation>Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998 Sep;16(9):2977-85.</citation>
    <PMID>9738566</PMID>
  </reference>
  <reference>
    <citation>Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002 Dec;13(12):1893-8.</citation>
    <PMID>12453857</PMID>
  </reference>
  <reference>
    <citation>Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. doi: 10.1093/annonc/mdn717. Epub 2009 Jan 19.</citation>
    <PMID>19153121</PMID>
  </reference>
  <reference>
    <citation>Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994 Jul 1;54(13):3500-5.</citation>
    <PMID>8012973</PMID>
  </reference>
  <reference>
    <citation>Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 1993 Feb 15;53(4):799-805.</citation>
    <PMID>8428361</PMID>
  </reference>
  <reference>
    <citation>André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999 Nov;17(11):3560-8.</citation>
    <PMID>10550155</PMID>
  </reference>
  <reference>
    <citation>Royce ME, Hoff PM, Pazdur R. Progress in colorectal cancer chemotherapy: how far have we come, how far to go? Drugs Aging. 2000 Sep;17(3):201-16. Review.</citation>
    <PMID>11043819</PMID>
  </reference>
  <reference>
    <citation>Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother. 2003 Nov;57(9):412-5.</citation>
    <PMID>14652166</PMID>
  </reference>
  <reference>
    <citation>Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20. Review.</citation>
    <PMID>12422304</PMID>
  </reference>
  <reference>
    <citation>Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9. Epub 2007 May 24.</citation>
    <PMID>17522863</PMID>
  </reference>
  <reference>
    <citation>Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.</citation>
    <PMID>20728210</PMID>
  </reference>
  <reference>
    <citation>Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378.</citation>
    <PMID>18349393</PMID>
  </reference>
  <reference>
    <citation>Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 Jun;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. Epub 2008 Apr 18.</citation>
    <PMID>18422971</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>XELOX</keyword>
  <keyword>PHASE 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

